Mechanism of NLRC5 in diffuse large B-cell lymphoma

Abstract

Abstract:Diffuse large Bcell lymphoma (DLBCL) is the most common malignant lymphoma in China, which mostly starting from the lymph nodes. The studies find that the expression of NLRC5, member of nucleotidebinding oligomerization domainlike receptor (NLR) family, is evident in the lymphoid cells, which is likely to be an important basis for lymphocyte tumorigenesis. NLRC5 can block the nuclear factorκB (NFκB), a core component of signal transduction pathway, and affect the development of tumor. While continuing activation of NFκB is a necessary condition for DLBCL cell survival. Therefore, NLRC5 is likely to inhibit excessive inflammation, thereby inhibiting the function of DLBCL, which promises to be a new target for immunotherapy treatment of DLBCL.

Key words:Lymphoma, large B-cell, diffuse,NF-kappaB,Genes, MHC class Ⅰ,NLRC5

Quan Yanlong, Zhou Yingqiong. Mechanism of NLRC5 in diffuse large B-cell lymphoma[J]. Journal of International Oncology, 2015, 42(2): 157-160.

References

［1］ Meissner TB, Li A, Biswas A, et al. NLR family member NLRC5 is a transcriptional regulator of MHC class Ⅰ genes［J］. Proc Natl Acad Sci USA, 2010, 107(31): 13794-13799. ［2］ Ting JP, Kastner DL, Hoffman HM. CATERPILLERs,pyrin and hereditary immunological disorders［J］. Nat Rev Immunol, 2006, 6(3): 183-195. ［3］ Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition［J］. Nat Immunol, 2011, 12(2): 121-128. ［4］ Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large Bcell lymphoma defined by gene expression profiling［J］. Clin Cancer Res, 2005, 11(1): 28-40. ［5］ Tong Y, Cui J, Li Q, et al. Enhanced TLRinduced NFκB signaling and type Ⅰ interferon responses in NLRC5 deficient mice［J］. Cell Res, 2012, 22(5): 822835. ［6］ Staehli F, Ludigs K, Heinz LX, et al. NLRC5 deficiency selectively impairs MHC class Ⅰdependent lymphocyte killing by cytotoxic T cells［J］. J Immunol, 2012, 188(8): 3820-3828. ［7］ Benko S, Magalhaes JG, Philpott DJ, et al. NLRC5 limits the activation of inflammatory pathways［J］. J Immunol, 2010, 185(3): 1681-1691. ［8］ Kuenzel S, Till A, Winkler M, et al. The nucleotidebinding oligomerization domainlike receptor NLRC5 is involved in IFNdependent antiviral immune responses［J］. J Immunol, 2010, 184(4): 1990-2000. ［9］ Neerincx A, Lautz K, Menning M, et al. A role for the human nucleotidebinding domain, leucinerich repeatcontaining family member NLRC5 in antiviral responses［J］. Biol Chem, 2010, 285(34): 26223-26232. ［10］ Sen R, Baltimor D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences［J］. Cell, 1986, 46(5): 705-716. ［11］ Cui J, Zhu L, Xia X, et al. NLRC5 negatively regulates the NFkappaB and type Ⅰ interferon signaling pathways［J］. Cell, 2010, 141(3): 483-496. ［12］ Kumar H, Pandey S, Zou J, et al. NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections［J］. J Immunol, 2011, 186(2): 994-1000. ［13］ Compaqno M, Lim Wk, Grunn A, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large Bcell lymphoma［J］. Nature, 2009, 459(7247): 717-721. ［14］ Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large Bcell lymphoma into molecular subtypes with highaccuracy［J］. Clin Cancer Res, 2009, 15(17): 5494-5502. ［15］ Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ difuse large Bcell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cel1［J］. Blood, 2003, 101(2): 699-702. ［16］ Neerincx A, Castro W, Guarda G, et al. NLRC5, at the heart of antigen presentation［J］. Front Immunol, 2013, 4: 397. ［17］ Meissner TB, Li A, Liu YJ, et al. The nucleotidebinding domain of NLRC5 is critical for nuclear import and transactivation activity［J］. Biochem Biophys Res Commun, 2012, 418(4): 786-791. ［18］ Neerincx A, Rodriguez GM, Steimle V, et al. NLRC5 controls basal MHC class Ⅰ gene expression in an MHC enhanceosomedependent manner［J］. J Immunol, 2012, 188(10): 49404950. ［19］ Meissner TB, Liu YJ, Lee KH, et al. NLRC5 cooperates with the RFX transcription factor complex to induce MHC class Ⅰ gene expression［J］. J Immunol, 2012, 188(10): 49514958. ［20］ Yao Y, Wang Y, Chen F, et al. NLRC5 regulates MHC class Ⅰ antigen presentation in host defense against intracellular pathogens［J］. Cell Res, 2012, 22(5): 836-847. ［21］ Biswas A, Meissner TB, Kawai T, et al. Cutting edge: impaired MHC class Ⅰ expression in mice deficient for Nlrc5/Class Ⅰ transactivator［J］. J Immunol, 2012, 15, 189(2): 516-520. ［22］ Ting JP, Willingham SB, Bergstralh DT. NLRs at the intersection of cell death and immunity［J］. Nat Rev Immunol, 2008, 8(5): 372-379. ［23］ Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let7 MicroRNA, and IL6 links inflammation to cell transformation［J］. Cell, 2009, 139(4): 693-706.